Myeloid ecosystems in hepatocellular carcinoma: macrophage–neutrophil–MDSC crosstalk in immune escape and immunotherapy resistance
Translational Oncology · 2027-01 · 75 · 103117
DOI: 10.1016/j.tranon.2026.103117 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Translational Oncology, 2027-01. Verfasst von Wenshi Ou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Fujian Medical University, No. 20 Chazhong Road, Fuzhou, 350000, China; …. Die Arbeit nennt 201 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fujian Medical University.
Abstract (Originalsprache)
Immune checkpoint blockade has reshaped the treatment landscape of advanced hepatocellular carcinoma (HCC), yet durable responses remain limited to a subset of patients. Increasing evidence indicates that therapeutic resistance cannot be explained solely by T-cell exhaustion or PD-1/PD-L1 expression, but is actively shaped by an interconnected myeloid ecosystem. In HCC, tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), and myeloid-derived suppressor cells (MDSCs) integrate signals from oncogenic pathways, chronic liver injury, fibrosis, metabolic stress, vascular remodeling, and therapy-induced damage. TAM subsets such as TREM2⁺, MARCO⁺, and CX3CR1⁺ macrophages promote CD8⁺ T-cell exclusion, suppress innate immune sensing, and form spatially protected tumor niches. TANs contribute to immune escape through immunosuppressive neutrophil states, neutrophil extracellular traps, CD73-adenosine signaling, and direct impairment of CD8⁺ T cells. MDSCs expand in response to radiofrequency ablation, chemotherapy resistance, fibrosis-associated inflammation, and immune checkpoint pressure, reinforcing PD-L1-, VEGF-A-, S100A9-, and TGF-β-related suppression. This review summarizes recent experimental evidence defining macrophage-neutrophil-MDSC crosstalk in HCC immune escape and immunotherapy resistance. We also discuss how other therapeutic pressures, including locoregional therapy and chemotherapy, can reshape the myeloid ecosystem and thereby influence subsequent immune control. Finally, we highlight myeloid-targeted strategies, biomarker development, etiology-informed stratification, and ecosystem-guided combinations aimed at improving immunotherapy outcomes in HCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Fujian Medical University, No. 20 Chazhong Road, Fuzhou, 350000, China; Department of Hepatopancreatobiliary Surgery, National Regional Medica…
- Department of Cardiology, Union Hospital, Fujian Medical University, Fuzhou, 350000, China.
- Department of General Surgery Ward 1, Lianjiang County Hospital, Fuzhou, 350500, China.
Förderung
- Fujian Medical University
Zitieren
APA
Ou, W., Chen, M., Lin, X., & Hu, Y. (2027). Myeloid ecosystems in hepatocellular carcinoma: macrophage–neutrophil–MDSC crosstalk in immune escape and immunotherapy resistance. Translational Oncology, 75, 103117. https://doi.org/10.1016/j.tranon.2026.103117
Vancouver
Ou W, Chen M, Lin X, Hu Y. Myeloid ecosystems in hepatocellular carcinoma: macrophage–neutrophil–MDSC crosstalk in immune escape and immunotherapy resistance. Translational Oncology. 2027;75:103117. doi:10.1016/j.tranon.2026.103117
BibTeX
@article{Ou2027,
author = {Ou, Wenshi and Chen, Meiqi and Lin, Xingpeng and Hu, Yuhai},
title = {Myeloid ecosystems in hepatocellular carcinoma: macrophage–neutrophil–MDSC crosstalk in immune escape and immunotherapy resistance},
journal = {Translational Oncology},
year = {2027},
volume = {75},
pages = {103117},
doi = {10.1016/j.tranon.2026.103117}
}
EUVIMED